|
1）Derkx B, Taminiau J, Radema S, et al. Tumour-necrosis-factor antibody treatment in Crohnʼs disease. Lancet. 1993; 342: 173-4
|
|
|
|
2）Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003; 98: 1315-24
|
|
|
|
|
3）DHaens G, Baert F, Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohnʼs disease: an open randomized trial. Lancet. 2008; 371; 660-7
|
|
|
|
|
|
4）Regueiro M, Schraut W, Baidoo I, et al. Infliximab prevents Crohnʼs disease recurrence after ileal resection. Gastroenterology. 2009; 136: 441-50
|
|
|
|
|
|
5）Maser EA, Villela R, Silverberg MS, et al. Association of trough serum Infliximab to clinical outcome after schedule maintenance treatment for Crohnʼs disease. Clin Gastroenterol Hepatol. 2006; 4; 1248-53
|
|
|
|
|
|
6）Sanborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014; 146: 85-95
|
|
|
|
|
|
7）Sanborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014; 146: 96-109
|
|
|
|
|
|
8）Sanborn WJ, Feagan BG, Stoinov S, et al. certolizumab pegol for the treatment of Crohnʼs disease. N Engl Med. 2007; 357: 228-38
|
|
|
|
|
|
9）Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohnʼs disease. N Engl J Med. 2007; 357: 239-50
|
|
|
|
|
|
10）Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human antiinterleukin-6 receptor monoclonal antibody in active Crohnʼs disease. Gastroenterology. 2004; 126: 989-96
|
|
|
|
|
|
11）Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohnʼs disease. Gastroenterology. 2001; 121: 268-74
|
|
|
|
|
|
12）Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohnʼs disease. N Engl J Med. 2003; 348: 24-32
|
|
|
|
|
|
13）Sanborn WJ, Kcolombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohnʼs disease. N Engl Med. 2005; 353: 1912-25
|
|
|
|
|
|
14）Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369: 699-710
|
|
|
|
|
|
15）Sanborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohnʼs disease. N Engl J Med. 2013; 369: 711-21
|
|
|
|
|